You can buy or sell ONCY and other stocks, options, ETFs, and crypto commission-free!
Oncolytics Biotech, Inc. engages in the development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. It offers a non-pathogenic, properietary isolate of the reovirus that induce selective tumor lysis, and promotes an inflamed tumor phenotype through innate and adaptive immune responses. Read More The company was founded by Matthew C. Coffey and Bradley George Thompson on April 2, 1998 and is headquartered in Calgary, Canada.
52 Week High
52 Week Low
Yahoo FinanceMay 3
Oncolytics Biotech (R) Reports 2019 First Quarter Financial Results and Operational Highlights
- Recent biomarker data identifies a simple blood test that may predict clinical response to pelareorep - - Interim data from ongoing AWARE-1 window of opportunity breast cancer study expected in 2H 2019 - CALGARY, AB and SAN DIEGO, CA / ACCESSWIRE / May 3, 2019 / Oncolytics Biotech® Inc. (ONCY) (ONC.TO), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced its financial results and operational highlights for the quarter ended March 31, 2019. All dollar amoun...
Expected Aug 2, Pre-Market